Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Editorial commentary: network epidemic models: assumptions and interpretations.

Goyal R, Wang R, DeGruttola V.

Clin Infect Dis. 2012 Jul;55(2):276-8. doi: 10.1093/cid/cis388. Epub 2012 Apr 5. No abstract available.

2.

Predicting trends in HIV-1 sexual transmission in sub-Saharan Africa through the Drug Resource Enhancement Against AIDS and Malnutrition model: antiretrovirals for 5 reduction of population infectivity, incidence and prevalence at the district level.

Palombi L, Bernava GM, Nucita A, Giglio P, Liotta G, Nielsen-Saines K, Orlando S, Mancinelli S, Buonomo E, Scarcella P, Altan AM, Guidotti G, Ceffa S, Haswell J, Zimba I, Magid NA, Marazzi MC.

Clin Infect Dis. 2012 Jul;55(2):268-75. doi: 10.1093/cid/cis380. Epub 2012 Apr 5.

PMID:
22491503
3.

How does population viral load vary with the evolution of a large HIV epidemic in sub-Saharan Africa?

Abu-Raddad LJ, Awad SF.

AIDS. 2014 Mar 27;28(6):927-9. doi: 10.1097/QAD.0000000000000211.

4.

Challenges in the Elimination of Pediatric HIV-1 Infection.

Luzuriaga K, Mofenson LM.

N Engl J Med. 2016 Feb 25;374(8):761-70. doi: 10.1056/NEJMra1505256. Review. No abstract available.

PMID:
26933850
5.

Intermediate levels of transmitted antiretroviral drug resistance in Midwestern Brazil.

Pfrimer IA, Bizinoto MC, Brandão NA, Camargo M, Sucupira MC, Janini LM, Diaz RS.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):205-6. doi: 10.1089/AID.2012.0012. Epub 2012 Oct 9. No abstract available.

PMID:
22978276
6.

Impact of early-stage HIV transmission on treatment as prevention.

Powers KA, Kretzschmar ME, Miller WC, Cohen MS.

Proc Natl Acad Sci U S A. 2014 Nov 11;111(45):15867-8. doi: 10.1073/pnas.1418496111. Epub 2014 Nov 3. No abstract available.

7.

Transmitted drug resistance and antiretroviral treatment outcomes in non-subtype B HIV-1-infected patients in South East Asia.

Phanuphak P, Sirivichayakul S, Jiamsakul A, Sungkanuparph S, Kumarasamy N, Lee MP, Sirisanthana T, Kantipong P, Lee C, Kamarulzaman A, Mustafa M, Ditangco R, Merati T, Ratanasuwan W, Singtoroj T, Kantor R.

J Acquir Immune Defic Syndr. 2014 May 1;66(1):74-9. doi: 10.1097/QAI.0000000000000108.

8.

Prevention of early HIV transmissions might be more important in emerging or generalizing epidemics.

Vasylyeva TI, Friedman SR, Magiorkinis G.

Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):E1515. doi: 10.1073/pnas.1424168112. Epub 2015 Mar 3. No abstract available.

9.

Management of the HIV epidemic in Nicaragua: the need to improve information systems and access to affordable diagnostics.

Espinoza H, Sequeira M, Domingo G, Amador JJ, Quintanilla M, de los Santos T.

Bull World Health Organ. 2011 Aug 1;89(8):619-20. doi: 10.2471/BLT.11.086124. No abstract available.

10.

Antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.

Waweru C.

N Engl J Med. 2008 Oct 23;359(17):1845-6; author reply 1846-7. No abstract available.

PMID:
18949839
11.

Evidence gathered from randomized clinical trials and observational studies on the equivalence of emtricitabine and Lamivudine.

Rokx C, Rijnders BJ.

Clin Infect Dis. 2015 Jun 1;60(11):1732-3. doi: 10.1093/cid/civ117. Epub 2015 Feb 16. No abstract available.

PMID:
25690599
12.

Progress in human immunodeficiency virus care in prisons: still room for improvement?

Puisis M.

JAMA Intern Med. 2014 May;174(5):730-1. doi: 10.1001/jamainternmed.2014.521. No abstract available.

PMID:
24686833
13.

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

Hocqueloux L, Saez-Cirion A, Rouzioux C.

JAMA Intern Med. 2013 Mar 25;173(6):475-6. doi: 10.1001/jamainternmed.2013.2176. No abstract available.

PMID:
23529554
14.

Trends over time of virological and immunological characteristics in the Swiss HIV Cohort Study.

Ledergerber B, Cavassini M, Battegay M, Bernasconi E, Vernazza P, Hirschel B, Furrer H, Rickenbach M, Weber R; Swiss HIV Cohort Study.

HIV Med. 2011 May;12(5):279-88. doi: 10.1111/j.1468-1293.2010.00880.x. Epub 2010 Oct 18.

15.

Russia, the G8, and HIV.

[No authors listed]

Lancet. 2006 May 27;367(9524):1703. No abstract available.

PMID:
16731246
16.

What is the significance of posttreatment control of HIV infection vis-à-vis functional cure?

Vanham G, Buvé A, Florence E, Seguin-Devaux C, Sáez-Cirión A.

AIDS. 2014 Feb 20;28(4):603-5. doi: 10.1097/QAD.0000000000000147. No abstract available.

17.

Preexposure prophylaxis for HIV--where do we go from here?

Cohen MS, Baden LR.

N Engl J Med. 2012 Aug 2;367(5):459-61. doi: 10.1056/NEJMe1207438. Epub 2012 Jul 11. No abstract available.

18.

Modelling the epidemiological impact of scaling up HIV testing and antiretroviral treatment in China.

Zhang L, Gray RT, Wilson DP.

Sex Health. 2012 Jul;9(3):261-71. doi: 10.1071/SH11104.

PMID:
22697144
19.

Antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.

Mills J.

N Engl J Med. 2008 Oct 23;359(17):1846; author reply 1846-7. No abstract available.

PMID:
18949841
20.

Ex vivo models of HIV sexual transmission and microbicide development.

Ariën KK, Kyongo JK, Vanham G.

Curr HIV Res. 2012 Jan 1;10(1):73-8. Review.

PMID:
22264048

Supplemental Content

Support Center